Patents by Inventor Francesca Rocchetti

Francesca Rocchetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20250387504
    Abstract: Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an antibody or an antigen-binding fragment thereof covalently linked to at least one BH3 mimetic through a dual linker. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising at least one BH3 mimetic and methods of making the same are also disclosed.
    Type: Application
    Filed: May 19, 2023
    Publication date: December 25, 2025
    Inventors: Matthew T. Burger, Zhuoliang Chen, Joseph Anthony D'Alessio, Gregory John Hollingworth, Claudia Judith Klinter, Jean-Baptiste Langlois, Eric Andrew McNeill, Cornelia Anne Mundt, Katsumasa Nakajima, Richard Vaughan Newcombe, Katharina Madörin, Bing Yu, Qiang Zhang, Imre Fejes, Olivier Geneste, Ana Leticia Maragno, Stuart Ray, Francesca Rocchetti, Jérôme-Benoit Starck, Zoltán Szlavik, Vesela Kostova, Tibor Novák
  • MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20250339547
    Abstract: Anti-Met antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a Bcl-xL inhibitor drug moiety and an anti-Met antibody or antigen-binding fragment thereof that binds the antigen target, e.g., the antigen expressed on a tumor or other cancer cells. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making same are also disclosed.
    Type: Application
    Filed: May 19, 2023
    Publication date: November 6, 2025
    Inventors: Joseph Anthony D'Alessio, Zhuoliang Chen, Eric Andrew McNeill, Richard Vaughan Newcombe, Bing Yu, Ana Leticia Maragno, Michael Monrad Grandal, Vesela Kostova, Francesca Rocchetti, Tibor Novák, Jérôme-Benoit Starck, Gaëtane Le Toumelin-Braizat, Maïa Chanrion
  • 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-YL]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS
    Publication number: 20250179047
    Abstract: A compound of formula (I): wherein R3, R4, R5, R6, Z1, Z2 and T are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring anti-apoptotic inhibitors.
    Type: Application
    Filed: February 23, 2023
    Publication date: June 5, 2025
    Inventors: Annamária BALASSA, Paul Andrew BROUGH, Audrey CLAPERON, Didier DEMARLES, Imre FEJES, Eszter FÖRDÖS, Balázs KOMJÁTI, Daniel MADDOX, Balázs MOLNÁR, James Brooke MURRAY, Stuart RAY, Francesca ROCCHETTI, Emma SANDERS, Melinda SIPOS, Zoltán SIPOS, Zoltán SZLÁVIK, Claire Louise WALMSLEY, Yikang WANG
  • SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS
    Publication number: 20240150293
    Abstract: Compounds of Formula (I): wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring anti-apoptotic inhibitors.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 9, 2024
    Inventors: Stephen STOKES, Simon BEDFORD, l-Jen CHEN, James Edward Paul DAVIDSON, Nicholas DAVIES, Christopher John GRAHAM, Sean Martin MCKENNA, Johannes W.G. MEISSNER, James Brooke MURRAY, Rachel Jane PARSONS, Stuart RAY, Emma SANDERS, Claire Louise WALMSLEY, Paul Andrew BROUGH, András KOTSCHY, Ágnes PROSZENYÁK, Ádám SINAI, Balázs Károly BÁLINT, Márton CSÉKEI, Márton ZWILLINGER, Rita GARAMVÖLGYI, Szabolcs SIPOS, Vilibald KUN, Zoltán SZABÓ, Maïa CHANRION, Francesca ROCCHETTI, Frédéric COLLAND, Ana Leticia MARAGNO, Laura BRESSON
  • MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20240042051
    Abstract: Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
    Type: Application
    Filed: November 23, 2021
    Publication date: February 8, 2024
    Inventors: Matthew T. Burger, Zhuoliang Chen, Joseph Anthony D'Alessio, Claudia Judith Klinter, Eric McNeill, Cornelia Anne Mundt, Katsumasa Nakajima, Richard Vaughan Newcombe, Mark G. Palermo, Tamas Schweighoffer, Bing Yu, Katharina Winkelbach, Qiang Zhang, Laura Bresson, Frédéric Colland, Ana Leticia Maragno, Francesca Rocchetti
  • MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20230092679
    Abstract: Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
    Type: Application
    Filed: May 19, 2020
    Publication date: March 23, 2023
    Inventors: Matthew T. Burger, Maia Chanrion, Frédéric Colland, Marton Csekei, Lea Delacour, Patrice Desos, Olivier Geneste, Jean-Michel Henlin, Vesela Kostova, Andras Kotschy, Ana Leticia Maragno, Eric McNeill, Mark G. Palermo, Francesca Rocchetti, Jérôme Starck, Bing Yu, Qiang Zhang, Ágnes Proszenyák, Szabolcs Sipos, Zhuoliang Chen, Katsumasa Nakajima, Joseph Anthony D'Alessio
  • MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20230081720
    Abstract: Anti-CD74 antibody-drug conjugates are disclosed. The anti-CD74 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD74 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
    Type: Application
    Filed: May 19, 2020
    Publication date: March 16, 2023
    Inventors: Matthew T. Burger, Maia Chanrion, Frédéric Colland, Marton Csekei, Lea Delacour, Patrice Desos, Olivier Geneste, Jean-Michel Henlin, Vesela Kostova, Andras Kotschy, Ana Leticia Maragno, Eric McNeill, Mark G. Palermo, Francesca Rocchetti, Jérôme Starck, Bing Yu, Qiang Zhang, Ágnes Proszenyák, Szabolcs Sipos, Zhuoliang Chen, Katsumasa Nakajima, Joseph Anthony D'Alessio, John William Blankenship